Herrera-Restrepo O, Bunniran S, Mond T, Davenport E, Wang J, Marshall G. Knowledge of invasive meningococcal disease and vaccination recommendations for adolescents and young adults among US physicians. Poster presented at the SAHM 2023 Annual Meeting; March 7, 2023. Baltimore, MD.

Neisseria meningitidis is a leading cause of life-threatening meningitis and sepsis in the United States (US). The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommends vaccination against meningococcal serogroups A, C, W, and Y (MenACWY) for all 11–12-year-old adolescents, with a booster dose at age 16. Additionally, the ACIP recommends vaccination against meningococcal serogroup B (MenB) at age 16–23 (preferably age 16–18) under shared clinical decision making (SCDM) between patients/caregivers and providers. However, uptake of the MenACWY booster dose and the MenB vaccination series is low. To shed light on this problem, this study evaluated US physicians’ understanding of meningococcal disease epidemiology and their knowledge of vaccination recommendations.


Share on: